Statements of Cash Flows - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net loss	$ (5,052,240)	$ (7,713,679)	$ (11,817,028)	$ (15,305,099)
Losses in equity investment in Aytu BioScience, Inc.	690,834		1,043,353
Stock-based compensation and warrant modification			919,572	2,785,557
Depreciation and amortization			611,065	412,409
Amortization of prepaid research and development - related party (Note 7)			71,900	71,901
Common stock issued for services			60,000	30,000
Adjustments to reconcile net loss to net cash used in operating activities
Increase in prepaid expenses			(316,964)	(158,556)
Decrease in accounts receivable from Aytu BioScience, Inc.			38,451
Decrease in accounts payable			(435,404)	(1,701,509)
Decrease in deferred rent			(19,021)	(14,184)
Increase in accrued compensation			297,438	595,957
Net cash used in operating activities - continuing operations			(9,546,638)	(13,283,524)
Net cash provided by operating activities - discontinued operations				852,328
Net cash used in operating activities			(9,546,638)	(12,431,196)
Cash flows used in investing activities
Purchase of fixed assets				(84,451)
Net cash used in investing activities - continuing operations				(84,451)
Net cash used in investing activities - discontinued operations				(1,002,888)
Net cash used in investing activities				(1,087,339)
Cash flows from financing activities
Net cash used in financing activities - discontinued operations				(18,741)
Net cash used in financing activities				(18,741)
Net change in cash and cash equivalents			(9,546,638)	(13,537,276)
Cash and cash equivalents at beginning of period	26,957,938	50,159,751	26,957,938	50,159,751
Cash and cash equivalents - Aytu BioScience, Inc. at beginning of period	(10,959,546)	160,905	(10,959,546)	160,905
Cash and cash equivalents of Ampio Pharmaceuticals, Inc. at the beginning of period			15,998,392	50,320,656
Cash and cash equivalents at end of period	$ 6,451,754	$ 36,783,380	6,451,754	36,783,380
Non-cash transactions:
Distribution to stockholders			$ 13,018,687
Fixed asset purchases included in accounts payable				$ 24,860